Top Markets
Coin of the day
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Rang in aandelen #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Aandeelprijs
$2.65
Laatst gesynchroniseerd: 2024-04-03
Marktkapitalisatie
$115.71M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Kinnate Biopharma Inc. (KNTE)

Categorie

Dividendrendementgeschiedenis voor Kinnate Biopharma Inc. (KNTE)
Het dividendrendement (TTM) van Kinnate Biopharma Inc. (aandelsymbool: KNTE) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Kinnate Biopharma Inc. (KNTE) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH